Sbir 2009 topic 255- title: pyridinopyrimide analogs

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200900083C
Awardee
Awarding agency
Obligated
$152,363

Award facts

Opportunity
Contract value 100% obligated
$152,363.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541711 Research and Development in Biotechnology
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 26 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Palo Alto, CA 94303, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

About this award

The U.S. government awarded a $152,363 Small Business Innovation Research (SBIR) Program Phase I contract to LEO Therapeutics, LLC for research on "PYRIDINOPYRIMIDE ANALOGS" under the SBIR 2009 TOPIC 255 solicitation. The definitive, firm-fixed-price contract was awarded by a U.S. government agency and has a period of performance through March 31, 2010. The work will be performed in Palo Alto, California.

Quick answers

Who was awarded contract HHSN261200900083C?

HHSN261200900083C was awarded to LEO Therapeutics, LLC by National Cancer Institute (National Institutes of Health) on September 30, 2009.

How much is contract HHSN261200900083C worth?

The government has obligated $152,363 on HHSN261200900083C.

Was contract HHSN261200900083C competed?

The extent of competition for HHSN261200900083C was full and open competition after exclusion of sources. The government received 26 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award